Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study
Open Access
- 16 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10), e77691
- https://doi.org/10.1371/journal.pone.0077691
Abstract
Non-adherence is one of the strongest predictors of therapeutic failure in HIV-positive patients. Virologic failure with subsequent emergence of resistance reduces future treatment options and long-term clinical success. Prospective observational cohort study including patients starting new class of antiretroviral therapy (ART) between 2003 and 2010. Participants were naïve to ART class and completed ≥1 adherence questionnaire prior to resistance testing. Outcomes were development of any IAS-USA, class-specific, or M184V mutations. Associations between adherence and resistance were estimated using logistic regression models stratified by ART class. Of 314 included individuals, 162 started NNRTI and 152 a PI/r regimen. Adherence was similar between groups with 85% reporting adherence ≥95%. Number of new mutations increased with increasing non-adherence. In NNRTI group, multivariable models indicated a significant linear association in odds of developing IAS-USA (odds ratio (OR) 1.66, 95% confidence interval (CI): 1.04-2.67) or class-specific (OR 1.65, 95% CI: 1.00-2.70) mutations. Levels of drug resistance were considerably lower in PI/r group and adherence was only significantly associated with M184V mutations (OR 8.38, 95% CI: 1.26-55.70). Adherence was significantly associated with HIV RNA in PI/r but not NNRTI regimens. Therapies containing PI/r appear more forgiving to incomplete adherence compared with NNRTI regimens, which allow higher levels of resistance, even with adherence above 95%. However, in failing PI/r regimens good adherence may prevent accumulation of further resistance mutations and therefore help to preserve future drug options. In contrast, adherence levels have little impact on NNRTI treatments once the first mutations have emerged.Keywords
This publication has 41 references indexed in Scilit:
- Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing RegimensPLOS ONE, 2012
- Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureAIDS, 2012
- Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment FailureJAMA, 2011
- Antiretroviral medication adherence and the development of class-specific antiretroviral resistanceAIDS, 2009
- The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over TimeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug ClassesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Detection of Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant HIV‐1 after Discontinuation of Virologically Suppressive Antiretroviral TherapyClinical Infectious Diseases, 2008
- Modeling the HIV Protease Inhibitor Adherence–Resistance Curve by Use of Empirically Derived EstimatesThe Journal of Infectious Diseases, 2004
- Paradoxes of adherence and drug resistance to HIV antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2004